[
  {
    "ts": null,
    "headline": "Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both. At 30 weeks, Mounjaro met the primary and all key secondary endpoints, achieving superior improvements in A1C and body mass index (BMI) compared to placeb",
    "url": "https://finnhub.io/api/news?id=69449806ed97261fcb25ec2ac951d33364693893304e91b55cbdd34dddd1a5dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758150060,
      "headline": "Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes",
      "id": 136797583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both. At 30 weeks, Mounjaro met the primary and all key secondary endpoints, achieving superior improvements in A1C and body mass index (BMI) compared to placeb",
      "url": "https://finnhub.io/api/news?id=69449806ed97261fcb25ec2ac951d33364693893304e91b55cbdd34dddd1a5dc"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
    "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
    "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758142593,
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "id": 136791560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
      "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs",
    "summary": "One of the drugmaker's biggest U.S. manufacturing commitments.",
    "url": "https://finnhub.io/api/news?id=4b8e343a033f47d6a20eff2c5c05aab670e5bf2796634211aab0155fcde54426",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758142342,
      "headline": "Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs",
      "id": 136791561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One of the drugmaker's biggest U.S. manufacturing commitments.",
      "url": "https://finnhub.io/api/news?id=4b8e343a033f47d6a20eff2c5c05aab670e5bf2796634211aab0155fcde54426"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drug giants face sternest test yet",
    "summary": "There's a challenge with high-stakes GLP-1 medication that no one in pharma can ignore.",
    "url": "https://finnhub.io/api/news?id=5c5ed78765c3ee2bbaab154c110c9a381ddbe2c045a68a6040b4484198bc16e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758135780,
      "headline": "Weight-loss drug giants face sternest test yet",
      "id": 136791562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There's a challenge with high-stakes GLP-1 medication that no one in pharma can ignore.",
      "url": "https://finnhub.io/api/news?id=5c5ed78765c3ee2bbaab154c110c9a381ddbe2c045a68a6040b4484198bc16e3"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s orforglipron trumps oral semaglutide in head-to-head trial",
    "summary": "In the head-to-head trial, Lilly’s oral drug emerged on top, outperforming Novo Nordisk’s semaglutide.",
    "url": "https://finnhub.io/api/news?id=bcf6b8d1857427ff35140531d4024fa7eed83e82fbd048924d776ec042a028a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758131804,
      "headline": "Lilly’s orforglipron trumps oral semaglutide in head-to-head trial",
      "id": 136791563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the head-to-head trial, Lilly’s oral drug emerged on top, outperforming Novo Nordisk’s semaglutide.",
      "url": "https://finnhub.io/api/news?id=bcf6b8d1857427ff35140531d4024fa7eed83e82fbd048924d776ec042a028a1"
    }
  },
  {
    "ts": null,
    "headline": "GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years",
    "summary": "GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.",
    "url": "https://finnhub.io/api/news?id=54da60dbd99115be1f3d2eef397a4baacdab16620b18cf8a5a7526d046d222b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758128160,
      "headline": "GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years",
      "id": 136791564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.",
      "url": "https://finnhub.io/api/news?id=54da60dbd99115be1f3d2eef397a4baacdab16620b18cf8a5a7526d046d222b0"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Markets Await Fed Rate Decision; China Regulator Reportedly Bans Nvidia Chip Sales to Alibaba, ByteDance",
    "summary": "The Dow Jones Industrial Average was up in late-morning trading Wednesday, while the S&P 500 and the",
    "url": "https://finnhub.io/api/news?id=92e7819956936be5ddd6f41a147bdcafd01cabc0218f4a4b06c6cf4c2a7f748f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758127461,
      "headline": "Top Midday Stories: Markets Await Fed Rate Decision; China Regulator Reportedly Bans Nvidia Chip Sales to Alibaba, ByteDance",
      "id": 136789824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was up in late-morning trading Wednesday, while the S&P 500 and the",
      "url": "https://finnhub.io/api/news?id=92e7819956936be5ddd6f41a147bdcafd01cabc0218f4a4b06c6cf4c2a7f748f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
    "summary": "Amid a flurry of news out of the world’s leading weight-loss drugmakers  Novo Nordisk  and  Eli Lilly  this week, Berenberg broke with the common Wall Street view that Lilly is the better obesity play.  Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy from Hold Tuesday.  The analysts see opportunities for new CEO Maziar Mike Doustdar to positively surprise investors, even as some hurdles remain.",
    "url": "https://finnhub.io/api/news?id=8287bf6d47aa41b907027b7d5c8311be76a499e4da021bcb45b936df97e40389",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758126360,
      "headline": "Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says",
      "id": 136791565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amid a flurry of news out of the world’s leading weight-loss drugmakers  Novo Nordisk  and  Eli Lilly  this week, Berenberg broke with the common Wall Street view that Lilly is the better obesity play.  Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy from Hold Tuesday.  The analysts see opportunities for new CEO Maziar Mike Doustdar to positively surprise investors, even as some hurdles remain.",
      "url": "https://finnhub.io/api/news?id=8287bf6d47aa41b907027b7d5c8311be76a499e4da021bcb45b936df97e40389"
    }
  },
  {
    "ts": null,
    "headline": "LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?",
    "summary": "Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.",
    "url": "https://finnhub.io/api/news?id=1211b38b2609d7a320cf421a4242040d461a680f00716c0954ebe130a8e4e929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758126120,
      "headline": "LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?",
      "id": 136791566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.",
      "url": "https://finnhub.io/api/news?id=1211b38b2609d7a320cf421a4242040d461a680f00716c0954ebe130a8e4e929"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Popped Today",
    "summary": "Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?",
    "url": "https://finnhub.io/api/news?id=4f8527ec4985e170b9c1b37267d389196b8572f1773d796d894c9d663add5ba2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758124967,
      "headline": "Why Novo Nordisk Stock Popped Today",
      "id": 136789890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?",
      "url": "https://finnhub.io/api/news?id=4f8527ec4985e170b9c1b37267d389196b8572f1773d796d894c9d663add5ba2"
    }
  },
  {
    "ts": null,
    "headline": "Lyft & Waymo, Eli Lilly, Opendoor: Trending Tickers",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including ride-share giant Lyft's (LYFT) partnership with driverless vehicle operator Waymo, the latest trial results from Eli Lilly's (LLY) oral weight-loss drug pill, and Opendoor Technologies (OPEN) and new CEO Kaz Nejatian's 8-K filings for their social media accounts. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=1b7062963099d3ef78e7240053e081c2636e1c7c757426dc04a2b661d19e21d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758123844,
      "headline": "Lyft & Waymo, Eli Lilly, Opendoor: Trending Tickers",
      "id": 136789866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including ride-share giant Lyft's (LYFT) partnership with driverless vehicle operator Waymo, the latest trial results from Eli Lilly's (LLY) oral weight-loss drug pill, and Opendoor Technologies (OPEN) and new CEO Kaz Nejatian's 8-K filings for their social media accounts. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=1b7062963099d3ef78e7240053e081c2636e1c7c757426dc04a2b661d19e21d8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's GLP-1 Pill Outperforms Older Novo Drug",
    "summary": "Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on \"Bloomberg Open Interest.\"",
    "url": "https://finnhub.io/api/news?id=eb2af1fe1c63847b61b52e0d1b9a7b9aa5616367b45247766fe8b914bb27e440",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758123450,
      "headline": "Lilly's GLP-1 Pill Outperforms Older Novo Drug",
      "id": 136789892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on \"Bloomberg Open Interest.\"",
      "url": "https://finnhub.io/api/news?id=eb2af1fe1c63847b61b52e0d1b9a7b9aa5616367b45247766fe8b914bb27e440"
    }
  },
  {
    "ts": null,
    "headline": "Data on Eli Lilly’s Weight Loss Pill Haven’t Thrilled Investors. New Updates Are Complicating the Picture.",
    "summary": "The drugmaker  Eli Lilly’s  reign as the undisputed king of the weight loss trade came under threat in early August, after disappointing preliminary data on its closely watched experimental weight loss pill set off a 14% single-day selloff.  Investors had hoped that Lilly’s experimental pill, orforglipron, would work better as an obesity treatment than  Novo Nordisk’s  injection Wegovy, and that patients looking for a more convenient option might choose it instead.  An oral version of Wegovy, now under Food and Drug Administration review, has also demonstrated 15% weight loss.",
    "url": "https://finnhub.io/api/news?id=ace1234138b36060fe494ca2e227e412561777d25fb0d330c46d4362853e2c14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758123300,
      "headline": "Data on Eli Lilly’s Weight Loss Pill Haven’t Thrilled Investors. New Updates Are Complicating the Picture.",
      "id": 136789893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker  Eli Lilly’s  reign as the undisputed king of the weight loss trade came under threat in early August, after disappointing preliminary data on its closely watched experimental weight loss pill set off a 14% single-day selloff.  Investors had hoped that Lilly’s experimental pill, orforglipron, would work better as an obesity treatment than  Novo Nordisk’s  injection Wegovy, and that patients looking for a more convenient option might choose it instead.  An oral version of Wegovy, now under Food and Drug Administration review, has also demonstrated 15% weight loss.",
      "url": "https://finnhub.io/api/news?id=ace1234138b36060fe494ca2e227e412561777d25fb0d330c46d4362853e2c14"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Says Its Obesity Drug Tops Novo Nordisk’s Oral Pill in Diabetes Trial",
    "summary": "The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.",
    "url": "https://finnhub.io/api/news?id=e998635d14f5f1eb7bfa43b20136f4520aa3def738e5cf77007e658c0e226916",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758122220,
      "headline": "Lilly Says Its Obesity Drug Tops Novo Nordisk’s Oral Pill in Diabetes Trial",
      "id": 136791567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.",
      "url": "https://finnhub.io/api/news?id=e998635d14f5f1eb7bfa43b20136f4520aa3def738e5cf77007e658c0e226916"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity",
    "summary": "Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.",
    "url": "https://finnhub.io/api/news?id=047d173b8a36b89dcf28a0d32c1d0484d924e0d3486d6c60e58440b40a2c8a42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758120780,
      "headline": "NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity",
      "id": 136789894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.",
      "url": "https://finnhub.io/api/news?id=047d173b8a36b89dcf28a0d32c1d0484d924e0d3486d6c60e58440b40a2c8a42"
    }
  },
  {
    "ts": null,
    "headline": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
    "summary": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=6f04ba293e7bafcfb5742f154a80a10737b7e5f994c48bd5f4c727370ba6ed17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119599,
      "headline": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
      "id": 136789007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Netflix upgraded, Five Below initiated: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=6f04ba293e7bafcfb5742f154a80a10737b7e5f994c48bd5f4c727370ba6ed17"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms",
    "summary": "Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial momentum and market leadership. Learn more about LLY stock here.",
    "url": "https://finnhub.io/api/news?id=bc706d1d00a106e4298e7d6fe8029bf76fa630b254662153d961913dc28932eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758119139,
      "headline": "Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms",
      "id": 136790916,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306661456/image_1306661456.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial momentum and market leadership. Learn more about LLY stock here.",
      "url": "https://finnhub.io/api/news?id=bc706d1d00a106e4298e7d6fe8029bf76fa630b254662153d961913dc28932eb"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Diabetes Drug Outperforms Novo in New Trial",
    "summary": "Eli Lilly & Co. Chief Scientific Officer Dan Skovronsky talks about the company's experimental diabetes pill orforglipron. In test trials, Lilly says patients on orforglipron lost more weight and had lower blood sugar levels than those on an older drug from rival Novo Nordisk. He speaks to Bloomberg's Katie Greifeld and Romaine Bostick.",
    "url": "https://finnhub.io/api/news?id=94a1c6c9b0ecd02a06664b48127dafbd6f4ea1194644cfbe2d2980a10c412b32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758117966,
      "headline": "Lilly's Diabetes Drug Outperforms Novo in New Trial",
      "id": 136789895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Co. Chief Scientific Officer Dan Skovronsky talks about the company's experimental diabetes pill orforglipron. In test trials, Lilly says patients on orforglipron lost more weight and had lower blood sugar levels than those on an older drug from rival Novo Nordisk. He speaks to Bloomberg's Katie Greifeld and Romaine Bostick.",
      "url": "https://finnhub.io/api/news?id=94a1c6c9b0ecd02a06664b48127dafbd6f4ea1194644cfbe2d2980a10c412b32"
    }
  },
  {
    "ts": null,
    "headline": "Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?",
    "summary": "Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg, and 36 mg) of orforglipron met the primary endpoint of superior body weight reduction compared to placebo. In addition, all three doses delivered clinically meaningful results compared to placebo across the",
    "url": "https://finnhub.io/api/news?id=83117ce81f77ac9de347e755e5a1e2da52b2e2575dbd0a0791292b69049534c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758117650,
      "headline": "Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?",
      "id": 136789008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg, and 36 mg) of orforglipron met the primary endpoint of superior body weight reduction compared to placebo. In addition, all three doses delivered clinically meaningful results compared to placebo across the",
      "url": "https://finnhub.io/api/news?id=83117ce81f77ac9de347e755e5a1e2da52b2e2575dbd0a0791292b69049534c2"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from ACHIEVE-3, an open-label randomized Phase 3 clinical trial evaluating the safety and efficacy of orforglipron compared to oral semaglutide, administered according to approved label instructions, in 1,698 adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial compared orforglipron (12 mg and 36 mg) to oral semaglutide (7 mg and 14 mg) across four active treatment arms to assess glycemic",
    "url": "https://finnhub.io/api/news?id=fd61efd90c5e944640df0bf71f58873c8705d5d286d00ffb886c8e23ee01c759",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758117600,
      "headline": "Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial",
      "id": 136789009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from ACHIEVE-3, an open-label randomized Phase 3 clinical trial evaluating the safety and efficacy of orforglipron compared to oral semaglutide, administered according to approved label instructions, in 1,698 adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial compared orforglipron (12 mg and 36 mg) to oral semaglutide (7 mg and 14 mg) across four active treatment arms to assess glycemic",
      "url": "https://finnhub.io/api/news?id=fd61efd90c5e944640df0bf71f58873c8705d5d286d00ffb886c8e23ee01c759"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats",
    "summary": "GSK (GSK), Eli Lilly (LLY), Johnson & Johnson (JNJ), and AstraZeneca (AZN) are among the pharmaceuti",
    "url": "https://finnhub.io/api/news?id=0391d40fd1d92ee20691e8302b10d5c911a6ae79c93fb6c88b523c8e6df64236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758117040,
      "headline": "Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats",
      "id": 136789010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK (GSK), Eli Lilly (LLY), Johnson & Johnson (JNJ), and AstraZeneca (AZN) are among the pharmaceuti",
      "url": "https://finnhub.io/api/news?id=0391d40fd1d92ee20691e8302b10d5c911a6ae79c93fb6c88b523c8e6df64236"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma flinches on Trump tariffsL Eli Lilly, GSK promise investment",
    "summary": "The pharma giants' multibillion spending promises come as drugmakers look to mitigate the threat of levies on imported medicines",
    "url": "https://finnhub.io/api/news?id=c04c7fa1cd9f998df01a6c045b948774ea7e94d902ff5236c81b9d2413c91597",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758114246,
      "headline": "Big Pharma flinches on Trump tariffsL Eli Lilly, GSK promise investment",
      "id": 136789011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giants' multibillion spending promises come as drugmakers look to mitigate the threat of levies on imported medicines",
      "url": "https://finnhub.io/api/news?id=c04c7fa1cd9f998df01a6c045b948774ea7e94d902ff5236c81b9d2413c91597"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Eli Lilly’s Valuation After Positive Obesity Drug Results and Major Virginia Facility Announcement",
    "summary": "If you follow Eli Lilly (LLY), chances are you have been watching closely as new data and expansion plans sent ripples through the stock market. The company just released detailed results from its pivotal Phase 3 ATTAIN-1 trial for orforglipron, an investigational oral GLP-1 drug. All three tested doses achieved superior body weight reduction in adults with obesity, which could make orforglipron a major entrant in a fast-growing market. In addition, Eli Lilly revealed it will build a $5...",
    "url": "https://finnhub.io/api/news?id=95a8e981f07b16d86178000223d060a75a3b696bbac62a80155893eaf3124c0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758113107,
      "headline": "Assessing Eli Lilly’s Valuation After Positive Obesity Drug Results and Major Virginia Facility Announcement",
      "id": 136787467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If you follow Eli Lilly (LLY), chances are you have been watching closely as new data and expansion plans sent ripples through the stock market. The company just released detailed results from its pivotal Phase 3 ATTAIN-1 trial for orforglipron, an investigational oral GLP-1 drug. All three tested doses achieved superior body weight reduction in adults with obesity, which could make orforglipron a major entrant in a fast-growing market. In addition, Eli Lilly revealed it will build a $5...",
      "url": "https://finnhub.io/api/news?id=95a8e981f07b16d86178000223d060a75a3b696bbac62a80155893eaf3124c0f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly picks Virginia for $5bn drug manufacturing plant",
    "summary": "The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over the next five years.",
    "url": "https://finnhub.io/api/news?id=131fb1a9da7936da902bcaf07e8d63833dcfb23cffbca5f8ec78f8bd6dfb8a08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758112260,
      "headline": "Eli Lilly picks Virginia for $5bn drug manufacturing plant",
      "id": 136787468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over the next five years.",
      "url": "https://finnhub.io/api/news?id=131fb1a9da7936da902bcaf07e8d63833dcfb23cffbca5f8ec78f8bd6dfb8a08"
    }
  },
  {
    "ts": null,
    "headline": "Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD",
    "summary": "Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”",
    "url": "https://finnhub.io/api/news?id=3573f7245ce873d1d8b103fba1481936dfe22f8834a5dde4155c7cd274ead975",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758111840,
      "headline": "Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD",
      "id": 136789896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”",
      "url": "https://finnhub.io/api/news?id=3573f7245ce873d1d8b103fba1481936dfe22f8834a5dde4155c7cd274ead975"
    }
  },
  {
    "ts": null,
    "headline": "Berenberg Downgrades Eli Lilly and (LLY)",
    "summary": "Berenberg Downgrades Eli Lilly and (LLY)",
    "url": "https://finnhub.io/api/news?id=091c907c43cfa743fd34feb250c091dc70bb4da0cdd0f05d36aceac82958a906",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758110595,
      "headline": "Berenberg Downgrades Eli Lilly and (LLY)",
      "id": 136788497,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=091c907c43cfa743fd34feb250c091dc70bb4da0cdd0f05d36aceac82958a906"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Eli Lilly Undecided on Using FDA Fast-Track Voucher for Weight-Loss Pill",
    "summary": "Eli Lilly's (LLY) international business president said it was too early to assume the company will",
    "url": "https://finnhub.io/api/news?id=a4be7d556dbe87e72f7f468c8d09929f1bf47ee1d7abfefa2a8e85180473c1ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758107263,
      "headline": "Market Chatter: Eli Lilly Undecided on Using FDA Fast-Track Voucher for Weight-Loss Pill",
      "id": 136787469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) international business president said it was too early to assume the company will",
      "url": "https://finnhub.io/api/news?id=a4be7d556dbe87e72f7f468c8d09929f1bf47ee1d7abfefa2a8e85180473c1ee"
    }
  },
  {
    "ts": null,
    "headline": "Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy",
    "summary": "VIENNA (Reuters) -Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president told Reuters on Wednesday.  Patrik Jonsson said that the drugmaker is applying a consumer-focused commercial strategy similar to its U.S. approach, including partnerships with telehealth and digital platforms to reach patients who are mainly paying for weight-loss drugs out-of-pocket, from Britain to China to the United Arab Emirates.  \"We learned very rapidly from the U.S. the importance of taking a very strong consumer focus,\" said Jonsson.",
    "url": "https://finnhub.io/api/news?id=9829bbf997053e5365875abd68d779142f28db842744d7e069f3b137b6202a93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758105564,
      "headline": "Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy",
      "id": 136787470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "VIENNA (Reuters) -Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president told Reuters on Wednesday.  Patrik Jonsson said that the drugmaker is applying a consumer-focused commercial strategy similar to its U.S. approach, including partnerships with telehealth and digital platforms to reach patients who are mainly paying for weight-loss drugs out-of-pocket, from Britain to China to the United Arab Emirates.  \"We learned very rapidly from the U.S. the importance of taking a very strong consumer focus,\" said Jonsson.",
      "url": "https://finnhub.io/api/news?id=9829bbf997053e5365875abd68d779142f28db842744d7e069f3b137b6202a93"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, EssilorLuxottica and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=5bd6f94da806daa298752339f1717788f9678fd64a85c365502d77d75bcd37b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758104760,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136787471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Novo Nordisk, EssilorLuxottica and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=5bd6f94da806daa298752339f1717788f9678fd64a85c365502d77d75bcd37b0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial",
    "summary": "Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial",
    "url": "https://finnhub.io/api/news?id=f917b3941a8f94290b7bf195ae4cb9aefce6e987ee32d96853eca7239f441314",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758104220,
      "headline": "Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial",
      "id": 136867251,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial",
      "url": "https://finnhub.io/api/news?id=f917b3941a8f94290b7bf195ae4cb9aefce6e987ee32d96853eca7239f441314"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill",
    "summary": "Eli Lilly's international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration's new fast-track review process for its experimental weight-loss pill orforglipron.  The FDA in July unveiled its \"Commissioner's National Priority Voucher\", under which certain experimental therapies addressing a chronic public health need and meeting specific criteria could be reviewed in one-to-two months, rather than the standard ten months.",
    "url": "https://finnhub.io/api/news?id=d342e78840c48e0ab165c8239277a6d6490c2217c07e07f94943adf32502d72f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758098620,
      "headline": "Eli Lilly cautious on using FDA fast-track voucher for weight-loss pill",
      "id": 136787472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration's new fast-track review process for its experimental weight-loss pill orforglipron.  The FDA in July unveiled its \"Commissioner's National Priority Voucher\", under which certain experimental therapies addressing a chronic public health need and meeting specific criteria could be reviewed in one-to-two months, rather than the standard ten months.",
      "url": "https://finnhub.io/api/news?id=d342e78840c48e0ab165c8239277a6d6490c2217c07e07f94943adf32502d72f"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
    "summary": "GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.",
    "url": "https://finnhub.io/api/news?id=a01c15214d596828c89c26f0ea4abcd12740f31abde9952ed26392baa8b4a7b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758070800,
      "headline": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
      "id": 136787473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.",
      "url": "https://finnhub.io/api/news?id=a01c15214d596828c89c26f0ea4abcd12740f31abde9952ed26392baa8b4a7b7"
    }
  },
  {
    "ts": null,
    "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "summary": "The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.",
    "url": "https://finnhub.io/api/news?id=73b9a38128f4de71fcb807dd3676ae230e993fe374b600e4d2c23aa40230f8a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758067260,
      "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "id": 136787474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.",
      "url": "https://finnhub.io/api/news?id=73b9a38128f4de71fcb807dd3676ae230e993fe374b600e4d2c23aa40230f8a6"
    }
  }
]